Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection
Death during MDR-TB treatment more likely in people with HIV and underweight or most drug-resistant patients
National HIV Prevention Conference highlights progress and disparities
United States faces biggest burden of hepatitis C treatment costs before 2020
New HIV cases decline in US, but population and geographic disparities persist
9-month MDR-TB regimen cures 82% in African study
San Francisco reports progress in 'Getting to Zero' HIV prevention and treatment effort
